General Home Investors News Uzedy

MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000

By MedincellJuly 27, 2022March 15th, 2024No Comments

MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000

July 27, 2022

Previous PostMedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report
Next PostMedinCell announces its full year financial results April 2021 - March 2022

Better medicine for all

Website by ScreenUp